Protecting Your Heart During Hormone Therapy:
IMPACT-ADT: Mitigating Cardiovascular Risks in Prostate Cancer Care - YouTube New Research Offers Hope BLUF (Bottom Line Up Front) A groundbreaking clinical trial at City of Hope is testing whether intermittent fasting or GLP-1 medications (like Ozempic) can protect prostate cancer patients from the cardiovascular risks of androgen deprivation therapy (ADT). This American Heart Association-funded study addresses a critical gap: most heart attacks in ADT patients occur within the first six months of treatment—before significant metabolic changes appear—suggesting an urgent need for early protective interventions. [See Sidebar: "Understanding Your Personal Risk Balance" for detailed analysis of when cardiovascular risk may outweigh cancer risk in your specific situation] The Cardiovascular Risk of Hormone Therapy When you start ADT for prostate cancer, your oncologist focuses on controlling your cancer. But cardiovascular disease represents a significant concurrent risk th...